on DocMorris AG (isin : CH0042615283)
DocMorris Reports Solid 11.1% Revenue Growth in 2025
DocMorris AG announced an increase in revenue by 11.1% in 2025, driven by strong performance in the fourth quarter. The Swiss online pharmacy reported a surge in digital services, highlighted by a 124% increase in TeleClinic revenue. The company's AI Health Companion saw significant adoption, with one-third of app users engaging with the AI assistant.
In Germany, DocMorris reported a 15.5% rise in external revenue during Q4. Prescription medication sales grew by 22.3% during the same period. Non-prescription revenue also displayed robust growth, fueled by both OTC sales and digital services.
Despite challenges such as the discontinuation of the Zur Rose brand, DocMorris successfully expanded its customer base to 11 million active customers by year-end. Going forward, the company forecasts achieving EBITDA breakeven in 2026.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all DocMorris AG news